Characteristic | Indolent (n = 12) | Transformed (n = 4) |
Age (y) | ||
Mean | 53.5 | 50.2 |
Range | 31–77 | 47–54 |
Sex | ||
Male | 6 | 2 |
Female | 6 | 2 |
Histology | ||
Follicular lymphoma grade I | 3 | |
Follicular lymphoma grade II | 7 | |
Small lymphocytic lymphoma or MALToma | 2 | |
Transformed | 4 | |
Initial follicular lymphoma internation prognostic index | ||
Low | 4 | 2 |
Intermediate | 4 | 1 |
High | 2 | 1 |
Disease evolution from diagnosis to study (y) | ||
Mean | 4.2 | 2.1 |
Range | 0.7–10.1 | 1.7–2.8 |
Prior chemo- or rituximab therapies | ||
Mean | 3.0 | 3.3 |
Range | 1–6 | 2–5 |
Previous radiotherapy | 2 | 2 |
Previous interferon-α treatment | 2 | Ø |
Stage at study entry | ||
II | 3 | |
III | 3 | 1 |
IV | 6 | 3 |
Bulky tumor at radioimmunotherapy (largest diameter ≥ 5 cm) | 11 | 2 |
Bone marrow involvement at radioimmunotherapy | 5 | 2 |
Elevated lactate dehydrogenase at radioimmunotherapy | 3 | 2 |
Reduced platelet counts at radioimmunotherapy | 2 | 2 |
Data represent number of patients, unless indicated otherwise.